Alterity Commences Mid-Stage Neurodegenerative Disorder Study By: Benzinga via Benzinga July 06, 2022 at 11:37 AM EDT Alterity Therapeutics (NASDAQ: ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System ... Read More >> Related Stocks: Alterity Therapeutics Ltd ADR